Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.72 USD | -0.37% | -6.53% | +8.80% |
Apr. 05 | Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit | MT |
Apr. 04 | Moderna Suffers Setback in Lawsuit by Arbutus | MT |
Sales 2024 * | 12.63M 9.18M | Sales 2025 * | 13.59M 9.88M | Capitalization | 673M 489M |
---|---|---|---|---|---|
Net income 2024 * | -113M -82.14M | Net income 2025 * | -130M -94.5M | EV / Sales 2024 * | 53.3 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 49.5 x |
P/E ratio 2024 * |
-6.18
x | P/E ratio 2025 * |
-5.2
x | Employees | 73 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 76.66% |
Latest transcript on Arbutus Biopharma Corporation
1 day | -0.37% | ||
1 week | -6.53% | ||
Current month | +5.43% | ||
1 month | +8.80% | ||
3 months | +15.25% | ||
6 months | +55.43% | ||
Current year | +8.80% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 49 | 14-06-30 | |
David Hastings
DFI | Director of Finance/CFO | 62 | 18-06-10 |
Karen Sims
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 68 | 14-11-30 | |
James Meyers
BRD | Director/Board Member | 58 | 18-10-22 |
Daniel Burgess
BRD | Director/Board Member | 62 | 17-03-22 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 0 M€ | 0.00% | - | |
0.03% | 0 M€ | 0.00% | - | |
0.03% | 2 M€ | -.--% | ||
0.02% | 7 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 2.72 | -0.37% | 931,457 |
24-04-18 | 2.73 | -1.80% | 1,016,821 |
24-04-17 | 2.78 | -4.79% | 710,512 |
24-04-16 | 2.92 | -1.68% | 644,013 |
24-04-15 | 2.97 | +2.06% | 3,626,020 |
Delayed Quote Nasdaq, April 19, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.80% | 490M | |
-5.99% | 83.66B | |
+2.76% | 40.41B | |
-24.88% | 28.26B | |
+53.61% | 24.53B | |
-8.08% | 16.82B | |
-33.74% | 13.39B | |
-16.63% | 11.75B | |
-11.19% | 11.69B | |
-2.25% | 8.13B |
- Stock Market
- Equities
- ABUS Stock